| 摘要: |
| 摘要:目的 探索美罗培南在新生儿中应用安全性情况,分析不良反应发生的危险因素,为临床安全使用美罗培南提供参考。方法 采用回顾性研究方法,利用中国医院药物警戒系统对聊城市人民医院2022年1月至2024年3月出院新生儿患儿中发生美罗培南相关不良反应的临床资料进行研究,利用Logistic等统计学方法分析不良反应发生的危险因素。结果 研究纳入367例病例,确定阳性病例63例。不良反应的表现以精神障碍及皮肤附件损害为主。临床转归显示症状缓解或消失56例。多因素分析提示年龄≤14 d、体重≥2.5 kg、疗程≥14 d是不良反应的独立危险因素(P<0.05)。结论 美罗培南在新生儿群体中的安全性较高,不良反应症状较轻,明确不良反应的危险因素有助于临床采取合理的干预及预防,提高新生儿人群使用美罗培南的安全性。 |
| 关键词: 美罗培南 新生儿 安全性 中国医院药物警戒系统 |
| DOI:10.13506/j.cnki.jpr.2026.03.017 |
| 基金项目:山东省药学会共享天晴、“药”有所为学术课题项目(No.Kjyw2024-14);山东省药学会医院合理用药天际健康中青年科研学术活动项目(第二期)(No.hlyy2024-08) |
|
|
|
| Analysis of adverse reactions and influencing factors of meropenem in the neonates |
| YANG Xue1,ZHANG Fan1,SUN Qian1,WANG Meirong2,ZHAO Ping1 |
| (1.Liaocheng People's Hospital,Liaocheng 252000,China;2.Gaomi People's Hospital,Gaomi 261500,China) |
| Abstract: |
| Abstract:Objective To explore the safety of meropenem application in neonates, analyze the risk factors for adverse reactions, and provide references for the safe use of meropenem in clinical practice.Methods The clinical data of meropenem related adverse reactions in newborns discharged from Liaocheng People's Hospital from January 2022 to March 2024 were analyzed by using the China Hospital Pharmacovigilance System. Logistic and other statistical methods were used to analyze the risk factors of adverse reactions.Results 367 cases were included in the study, and 63 positive cases were identified. The main adverse reactions were mental disorders and skin adnexal damage. Clinical outcome showed that 56 cases had relief or disappearance of symptoms. Multivariate analysis indicated that age ≤14 days, body weight ≥ 2.5 kg, duration ≥14 days were independent risk factors for adverse reactions (P<0.05).Conclusion Meropenem is relatively safe in neonates with mild adverse reaction symptoms. Identifying the risk factors of adverse reactions is helpful for clinical intervention and prevention, and improving the safety of using meropenem in neonates. |
| Key words: Meropenem Neonate Security China Hospital Pharmacovigilance System |